These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 24711223)

  • 21. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
    de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
    J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-surgical management of cystic prolactinomas.
    Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperprolactinaemia in males: a heterogeneous disorder.
    Walsh JP; Pullan PT
    Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
    Sosa-Eroza E; Espinosa-Cárdenas E
    Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
    Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
    Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.
    Behan LA; O'Sullivan EP; Glynn N; Woods C; Crowley RK; Tun TK; Smith D; Thompson CJ; Agha A
    J Endocrinol Invest; 2013; 36(7):508-14. PubMed ID: 23385474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
    Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
    Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
    Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
    Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
    Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.